Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158688 · ClinicalTrials.gov registry record · Phase 3
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT03158688 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 466 participants.
The verdict
NCT03158688, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2017-06-13 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03158688
The ClinicalTrials.gov registry entry for NCT03158688 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03158688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03158688 about?
NCT03158688 is a clinical study titled "Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.". Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
What is the current status of trial NCT03158688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2017-06-13. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT03158688?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT03158688?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.